Schistosomiasis and stunting: microbial and metabolic mechanisms in early childhood
Philosophical Transactions B · 14.05.2026 · 381 (1950)
DOI: 10.1098/rstb.2025.0094 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Philosophical Transactions B, online erschienen am 14.05.2026. Verfasst von Derick Nii Mensah Osakunor und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, GlasgowG12 8QQ, UK. Hauptthemen laut MEDLINE: Growth Disorders, Gastrointestinal Microbiome. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences, Thrasher Research Fund, British Academy.
Abstract (Originalsprache)
Stunting (low height-for-age > 2 s.d. below the WHO child growth standards median) is a key indicator of chronic malnutrition and is influenced by poor nutrition, infections, chronic inflammation and impaired gut health. In sub-Saharan Africa, stunting frequently occurs in regions where schistosomiasis is endemic. Our previous research in Zimbabwean preschool children (≤ 5 years) found that Schistosoma haematobium infection alone could account for up to one-third of stunting cases. Using epidemiological, gut microbiome and metabolomic analyses, we investigated how this parasitic infection contributes to poor growth. Infected children showed significantly altered gut microbiome profiles compared to uninfected peers, indicating potential microbiome disruption linked to disease and impaired development. Metabolomic profiling revealed that S. haematobium infection elevated energy- and purine-related metabolites, reflecting metabolic stress associated with malnutrition. Early treatment with praziquantel did not significantly alter the microbiome but did restore normal metabolic profiles, aligning with observed catch-up growth. Here, we synthesize findings from our studies and others to highlight opportunities for intervention and key research gaps, supporting the inclusion of praziquantel in early health programmes and integrated strategies combining treatment with nutrition. Further research, particularly longitudinal studies, is needed to confirm causality and optimize child health outcomes in endemic areas. This article is part of the theme issue ‘Biological, biomedical and environmental drivers of stunting’.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, GlasgowG12 8QQ, UK.
- Tackling Infections to Benefit Africa (TIBA) Partnership, University of Edinburgh, Edinburgh, UK.
- Centre for Immunity, Infection and Evolution, The University of Edinburgh Institute of Immunology and Infection Research, EdinburghEH9 3FL, UK.
- Department of Biochemistry and Biotechnology, University of Zimbabwe Faculty of Science, Harare,P.O. Box MP167, Zimbabwe.
- Tackling Infections to Benefit Africa (TIBA) Partnership, University of Zimbabwe, Harare, Harare Province, Zimbabwe.
ORCID-Profile: Derick Nii Mensah Osakunor, Lorraine Tsitsi Pfavayi, Takafira Mduluza, Francisca Mutapi
Förderung
- Academy of Medical Sciences
- Thrasher Research Fund
- British Academy
- Royal Society
Zitieren
APA
Osakunor, D. N. M., Pfavayi, L. T., Mduluza, T., & Mutapi, F. (2026). Schistosomiasis and stunting: microbial and metabolic mechanisms in early childhood. Philosophical Transactions B, 381(1950). https://doi.org/10.1098/rstb.2025.0094
Vancouver
Osakunor DNM, Pfavayi LT, Mduluza T, Mutapi F. Schistosomiasis and stunting: microbial and metabolic mechanisms in early childhood. Philosophical Transactions B. 2026;381(1950). doi:10.1098/rstb.2025.0094
BibTeX
@article{Osakunor2026,
author = {Osakunor, Derick Nii Mensah and Pfavayi, Lorraine Tsitsi and Mduluza, Takafira and Mutapi, Francisca},
title = {Schistosomiasis and stunting: microbial and metabolic mechanisms in early childhood},
journal = {Philosophical Transactions B},
year = {2026},
volume = {381},
number = {1950},
doi = {10.1098/rstb.2025.0094}
}
EUVIMED